Cleveland Clinic Florida, Weston, FL, USA.
UC Davis Health, Sacramento, CA, USA.
Pulm Pharmacol Ther. 2021 Feb;66:101979. doi: 10.1016/j.pupt.2020.101979. Epub 2020 Nov 28.
Treprostinil, a prostacyclin analogue used in the treatment of pulmonary arterial hypertension (PAH), is available for administration by parenteral, oral, or inhaled routes. Transitioning between routes may be beneficial for appropriate patients; however, there is little published data on transitions between oral and inhaled treprostinil. We used a modified Delphi process to develop expert consensus recommendations on transitions between these formulations. Three questionnaires were used to develop statements about relevant aspects of transition management, which the panelists rated, using a Likert scale, from -5 (strongly disagree) to +5 (strongly agree). Eleven physicians with expertise in PAH treatment modalities, participated in the panel. Of the 492 statements evaluated, consensus was reached on 215 (43.7%). Key consensus recommendations included (1) accurately defining successful transition, as stable or improved PAH with good tolerability and adherence, and (2) patients with stable, low-risk PAH showing insufficient response or tolerability to their existing treprostinil therapy (and due to restrictions in up titration of dosing), as appropriate candidates for transitions between treprostinil formulations. Panelists did not reach consensus for an overall strategy for performing these transitions, mainly because of variability in their practice parameters. Consensus was also achieved on recommendations for adverse event management, including reassurance, administration of oral treprostinil 3 times daily with food, and dosing inhaled treprostinil at intervals ≥3 hours apart. The Delphi process aided in developing expert consensus recommendations that may provide clinically useful guidance for transitioning between treprostinil formulations. However, additional data from centers with high volumes of PAH patients undergoing treprostinil transitions would be optimal for defining more complete and robust strategies to facilitate successful transition.
曲前列尼尔,一种前列环素类似物,用于治疗肺动脉高压(PAH),可通过注射、口服或吸入途径给药。在适当的患者中,转换途径可能是有益的;然而,关于口服和吸入曲前列尼尔之间的转换,发表的数据很少。我们使用改良 Delphi 过程制定了关于这些制剂之间转换的专家共识建议。使用三个问卷制定了关于过渡管理相关方面的陈述,专家小组成员使用李克特量表对这些陈述进行了评分,从-5(强烈不同意)到+5(强烈同意)。11 名具有 PAH 治疗方式专业知识的医生参加了小组讨论。在评估的 492 个陈述中,有 215 个(43.7%)达成了共识。关键的共识建议包括:(1)准确界定成功的过渡,即稳定或改善的 PAH,具有良好的耐受性和依从性;(2)对现有曲前列尼尔治疗有稳定、低风险的 PAH 患者,显示出足够的反应或耐受性,适当考虑曲前列尼尔制剂之间的转换。专家小组对进行这些转换的总体策略没有达成共识,主要是因为他们的实践参数存在差异。关于不良事件管理的建议也达成了共识,包括安慰、口服曲前列尼尔每日 3 次随餐服用,以及间隔≥3 小时分开使用吸入曲前列尼尔。Delphi 过程有助于制定专家共识建议,这些建议可能为曲前列尼尔制剂之间的转换提供临床有用的指导。然而,来自有大量 PAH 患者接受曲前列尼尔转换的中心的更多数据,将是定义更完整和更有力的策略以促进成功转换的最佳选择。